TABLE 3.
Outcomes of 21 patients with a diagnosis of malignancy before lung transplantation
| Patient |
Malignancy morphology |
Time between diagnosis of previous malignancy and transplant, years | Post-transplant outcome, years | Patient age at transplant, years (sex) | Indication for transplant | |
|---|---|---|---|---|---|---|
| Post-transplant | Pretransplant | |||||
| 1 | Squamous cell carcinoma of ear (2.1 years post-transplant) | Basal cell carcinoma of skin | 4.6 | Survival, 5.4 | 61.9 (Male) | Emphysema |
| Adenocarcinoma of sigmoid colon (4.1 years post-transplant) | Squamous cell carcinoma of lung | 0 (found in explanted lung) | ||||
| 2 | Post-transplant lymphoproliferative disorder (0.96 years post-transplant) | Squamous intraepithelial neoplasia of cervix | 6.4 | Survival, 3.6 | 31.2 (Female) | Cystic fibrosis |
| Adenocarcinoma of lung | 7 | |||||
| 3 | Squamous cell carcinoma of ear (1.9 years post-transplant) | Adenocarcinoma of prostate | 5.95 | Survival, 2.1 | 66.6 (Male) | Emphysema |
| 4 | Squamous cell carcinoma of skin at 4.9 years post-transplant | Squamous cell carcinoma of skin | 1.57 | Death (6.2 years post-transplant due to bronchiolitis obliterans) | 55.1 (Male) | Emphysema |
| 5 | Metastatic disease in liver and spine | Myxosarcoma of heart | 1.74 | Death (due to metastatic disease at 0.8 years post-transplant) | 19.6 (Female) | Cardiac sarcoma |
| 6 | Adenocarcinoma in breast | Adenocarcinoma of breast | 7.2 | Death (malignancy 0.79 years post-transplant) | 59.9 (Female) | Emphysema |
| 7 | None | Squamous cell carcinoma in explanted lung | 0 (found in explanted lung) | Survival, 3.8 | 50.1 (Female) | Pulmonary fibrosis |
| 8 | None | Adenocarcinoma of lung | 0 (found in explanted lung) | Survival, 1.42 | 63.2 (Male) | Emphysema |
| 9 | None | Squamous cell carcinoma of face and neck | 9.8 | Survival, 7.1 | 60 (Male) | Emphysema |
| 10 | None | Basal cell carcinoma of skin | 4.5 | Survival, 1.1 | 61.3 (Female) | Emphysema |
| 11 | None | Squamous cell carcinoma of cervix | 18.6 | Survival, 3.8 | 52 (Female) | Interstitial lung disease, pulmonary hypertension and scleroderma |
| 12 | None | Squamous cell carcinoma of uterus | 21.3 | Survival, 5 | 61 (Female) | Emphysema |
| 13 | None | Malignant melanoma of the choroid in the eye | 7.8 | Survival, 4.5 | 63 (Male) | Emphysema |
| 14 | None | Acute myeloid leukemia | 8.6 | Survival, 3.1 | 39.2 (Female) | Fibrosis of lungs due to graft versus host disease from bone marrow transplant |
| 15 | None | Renal cell carcinoma of kidney | 8.6 | 4.3 years post-transplant | 67.6 (Male) | Emphysema |
| 16 | None | Papillary transitional cell carcinoma of bladder | 5.6 | Survival, 0.9 | 60.1 (Male) | Emphysema |
| 17 | None | Malignant melanoma of skin | 0.75 | Survival, 1.9 | 43 (Female) | Alpha 1 anti-trypsin |
| 18 | None | Infiltrating duct adenocarcinoma of breast | 7.2 | Survival, 2 | 52.1 (Female) | Emphysema |
| 19 | None | Adenocarcinoma of lung | 4.3 | Survival, 0.5 | 67.4 (Female) | Emphysema |
| 20 | None | Squamous cell carcinoma of cervix | 27.4 | Death (1 year post-transplant due to infection) | 60.4 (Female) | Emphysema |
| 21 | None | Basal cell carcinoma of skin | 11.3 | Death (3 months post-transplant due to infection) | 57 (Female) | Pulmonary fibrosis |